Costello syndrome: genes and variants
Explore variant evidence for Costello syndrome across 15 analyzed proteins (HRAS, BRAF, ARAF, FGA, FGB and 10 more). Linked ClinVar records include 15 pathogenic or likely pathogenic variants, 199 variants of uncertain significance and 11 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Costello syndrome
HRAS: GTPase HRas
Its GTP-bound state activates RAF-MEK-ERK and other pathways downstream of growth-factor receptors. Somatic activating variants drive several cancers, while germline activating variants cause Costello syndrome.
15 ClinVar pathogenic / likely pathogenic and 209 uncertain variants in HRAS have source records linked to Costello syndrome. Association strength is not clinical gene validity.
BRAF: Serine/threonine-protein kinase B-raf
It relays activated RAS signals through MEK and ERK to control proliferation, differentiation, and survival. Activating variants, especially V600E, drive melanoma and several other cancers and create sensitivity to pathway-directed therapies.
0 ClinVar pathogenic / likely pathogenic and 1 uncertain variants in BRAF have source records linked to Costello syndrome. Association strength is not clinical gene validity.
ARAF: Serine/threonine-protein kinase A-Raf
It transmits RAS signals to the MEK-ERK pathway and participates in growth and developmental signaling. Activating germline or somatic variants can cause RASopathy phenotypes and have been identified as oncogenic drivers in selected tumors.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ARAF have source records linked to Costello syndrome. Association strength is not clinical gene validity.
FGA: Fibrinogen alpha chain
It contributes the alpha chains of fibrinogen, which thrombin converts into fibrin to form the structural mesh of blood clots. Pathogenic variants can cause afibrinogenemia, hypofibrinogenemia, dysfibrinogenemia, thrombosis, or certain hereditary amyloidoses.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in FGA have source records linked to Costello syndrome. Association strength is not clinical gene validity.
FGB: Fibrinogen beta chain
It contributes the beta chains required for assembly and secretion of functional fibrinogen and subsequent fibrin-clot formation. Pathogenic variants can reduce fibrinogen quantity or alter clot properties, producing bleeding, thrombosis, or both.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in FGB have source records linked to Costello syndrome. Association strength is not clinical gene validity.
FGG: Fibrinogen gamma chain
It contributes the gamma chains of fibrinogen and provides binding sites important for fibrin polymerization, platelet interactions, and clot stabilization. Pathogenic variants can cause quantitative or qualitative fibrinogen disorders and, in some alleles, hereditary renal amyloidosis.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in FGG have source records linked to Costello syndrome. Association strength is not clinical gene validity.
ITGA2B: Integrin alpha-IIb
Together with ITGB3, it forms the major platelet fibrinogen receptor that becomes activated during platelet stimulation and drives aggregation. Biallelic loss-of-function variants cause Glanzmann thrombasthenia, a severe inherited platelet-aggregation disorder.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ITGA2B have source records linked to Costello syndrome. Association strength is not clinical gene validity.
ITGB3: Integrin beta-3
In platelets it pairs with ITGA2B to bind fibrinogen and mediate aggregation, while in other cells it forms integrins involved in matrix adhesion and signaling. Biallelic loss-of-function variants cause Glanzmann thrombasthenia.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ITGB3 have source records linked to Costello syndrome. Association strength is not clinical gene validity.
MAP2K1: Dual specificity mitogen-activated protein kinase kinase 1
It phosphorylates ERK1 and ERK2 downstream of RAF and thereby propagates RAS-MAPK growth and developmental signals. Activating somatic variants occur in several cancers, while germline activating variants can cause cardio-facio-cutaneous syndrome and related RASopathies.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MAP2K1 have source records linked to Costello syndrome. Association strength is not clinical gene validity.
MAP2K2: Dual specificity mitogen-activated protein kinase kinase 2
It works with MEK1 to activate ERK signaling downstream of RAS and RAF. Germline activating variants can cause cardio-facio-cutaneous syndrome, while acquired activation can support oncogenic MAPK signaling and drug resistance.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MAP2K2 have source records linked to Costello syndrome. Association strength is not clinical gene validity.
MAPK1: Mitogen-activated protein kinase 1
It converts upstream RAS-RAF-MEK signaling into phosphorylation of cytoplasmic and nuclear targets controlling proliferation, differentiation, and development. Germline dysregulating variants can cause neurodevelopmental RASopathy phenotypes, while pathway hyperactivation is common in cancer.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MAPK1 have source records linked to Costello syndrome. Association strength is not clinical gene validity.
MAPK3: Mitogen-activated protein kinase 3
It works with ERK2 to transmit growth-factor and mitogen signals to transcriptional and cytoplasmic targets. Abnormal ERK activation is a hallmark of many RAS-MAPK-driven cancers and developmental syndromes.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MAPK3 have source records linked to Costello syndrome. Association strength is not clinical gene validity.
NRAS: GTPase NRas
Its active GTP-bound state drives RAF-MEK-ERK and PI3K signaling downstream of growth-factor receptors. Somatic activating variants are common drivers of melanoma, leukemia, and other cancers, while germline activating variants can cause Noonan syndrome.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in NRAS have source records linked to Costello syndrome. Association strength is not clinical gene validity.
SRC: Proto-oncogene tyrosine-protein kinase Src
It integrates signals from growth-factor receptors, integrins, and other surface proteins to regulate proliferation, adhesion, migration, and survival. Persistent SRC-family signaling promotes invasion and therapy resistance in many cancers and remains an important therapeutic target.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in SRC have source records linked to Costello syndrome. Association strength is not clinical gene validity.
VCL: Vinculin
It links integrins and cadherins to the actin cytoskeleton at focal adhesions and adherens junctions, transmitting mechanical force between cells and matrix. Pathogenic variants can cause dilated or hypertrophic cardiomyopathy and, in some cases, skeletal myopathy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in VCL have source records linked to Costello syndrome. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Costello syndrome
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| HRAS G12S | 12 | Pathogenic / likely pathogenic (★★★) | |
| HRAS G60D | 60 | Pathogenic / likely pathogenic (★★) | |
| HRAS G12E | 12 | Pathogenic / likely pathogenic (★★) | |
| HRAS G12V | 12 | Pathogenic / likely pathogenic (★★) | |
| HRAS G13V | 13 | Pathogenic / likely pathogenic (★★) | |
| HRAS G60V | 60 | Pathogenic / likely pathogenic (★★) | |
| HRAS E63K | 63 | Pathogenic / likely pathogenic (★★) | |
| HRAS A146V | 146 | Pathogenic / likely pathogenic (★★) | |
| HRAS Q22K | 22 | Pathogenic / likely pathogenic (★★) | |
| HRAS G60S | 60 | Pathogenic / likely pathogenic (★) | |
| HRAS G12R | 12 | Pathogenic / likely pathogenic (★) | |
| HRAS G13S | 13 | Pathogenic / likely pathogenic (★) | |
| HRAS A59L | 59 | Pathogenic / likely pathogenic (★) | |
| HRAS F156L | 156 | Pathogenic / likely pathogenic (★) | |
| HRAS A146T | 146 | Pathogenic / likely pathogenic |
Uncertain variants prioritized for review in Costello syndrome
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| HRAS G60R | 60 | Uncertain (★) | +7: 5 other pathogenic changes within 3 positions; G60V at the same position is pathogenic; seen in 6.8e-07 of gnomAD DNA copies; REVEL 0.941 | |
| HRAS A59S | 59 | Uncertain (★★) | +6: 4 other pathogenic changes within 3 positions; A59L at the same position is pathogenic; not seen in the gnomAD population database; AlphaMissense 0.95 |
Which prediction tools work for Costello syndrome
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 98 out of 100
- ESM1b (LLR): 96 out of 100
- CATVariant: 95 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 95 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 91 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 90 out of 100
- PolyPhen-2: 89 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 89 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- EVE: 83 out of 100
Same protein, different disease
- RASopathy also has ClinVar records linked to HRAS variants; they fall in the same places as the Costello syndrome variants (6 pathogenic / likely pathogenic).
- Epidermal nevus also has ClinVar records linked to HRAS variants; they fall in the same places as the Costello syndrome variants (3 pathogenic / likely pathogenic).
- Thyroid cancer, nonmedullary also has ClinVar records linked to HRAS variants; they fall in the same places as the Costello syndrome variants (3 pathogenic / likely pathogenic).
Diseases related to Costello syndrome
- Hypertrophic cardiomyopathy, also linked to ARAF, BRAF, FGA, FGB and 11 more
- Noonan syndrome, also linked to ARAF, BRAF, FGA, FGB and 11 more
- RASopathy, also linked to BRAF, HRAS, MAP2K1, MAP2K2 and 1 more
- Noonan syndrome and Noonan-related syndrome, also linked to BRAF, HRAS, MAP2K1, MAP2K2 and 1 more
- Cardiofaciocutaneous syndrome, also linked to BRAF, MAP2K1, MAP2K2 and NRAS
- Melanoma, also linked to BRAF, MAP2K1, MAP2K2 and NRAS
- Cardio-facio-cutaneous syndrome, also linked to BRAF, MAP2K1 and MAP2K2
- Familial dysfibrinogenemia, also linked to FGA, FGB and FGG
- Vascular malformation, also linked to BRAF, MAP2K1 and NRAS
- Afibrinogenemia, also linked to FGA, FGB and FGG
- Glanzmann thrombasthenia, also linked to ITGA2B and ITGB3
- Neurofibromatosis, also linked to MAP2K1 and MAP2K2
Frequently asked questions
Which genes have records linked to Costello syndrome?
This view contains 15 analyzed proteins: HRAS, BRAF, ARAF, FGA, FGB and 10 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 15 pathogenic or likely pathogenic variants, 199 variants of uncertain significance and 11 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 2 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 241 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center